Actemra SC — Medical Mutual
Systemic Juvenile Idiopathic Arthritis (SJIA)
Initial criteria
- Patient has tried one other systemic therapy (e.g., corticosteroid, conventional DMARD, 1-month NSAID trial, or one biologic other than tocilizumab); AND
 - Medication is prescribed by or in consultation with a rheumatologist
 
Reauthorization criteria
- Patient has been established on therapy for at least 6 months; AND
 - Patient experienced a beneficial clinical response assessed by objective measures OR patient experienced an improvement in at least one symptom compared with baseline
 
Approval duration
initial: 6 months; reauth: 1 year